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Background: Traditional Chinese Medicine (TCM) is one of the most popular complementary and alternative
medicine modalities worldwide. In Chinese and East Asian societies, TCM plays an active role in the modern health
care system and is even covered by the National Health Insurance Program of Taiwan. Liver cancer is the second
most common cancer in Taiwan. This study aimed to analyze the TCM utilization patterns of patients with liver
cancer from 1996–2007 using a population-based random sample of one million insured patients.
Methods: A cross-sectional study was conducted using registration and claim data sets from 1996 to 2007
obtained from the Longitudinal Health Insurance Database 2005 (LHID2005). The outpatient datasets contained the
encounter form-based dates of visit, three items from the International Classification of Diseases (Ninth Revision,
Clinical Modification codes), the primary procedure (e.g., drug or diagnostic procedure), type of copayment, billed
amount, and paid amount. Only ambulatory care was analyzed.
Results: A total of 6358 liver cancer patients utilized ambulatory care during the study period. Among them, 1240
(19.50%) availed of TCM outpatient services. The prevalence of TCM use fluctuated during the study period, with a
peak of 25.11% in 2001. After multivariable adjustment, the likelihood of TCM users was lower in participants aged
70 years and older (odds ratio, OR= 0.79, 95% confidence interval, CI: 0.64–0.97), males (OR= 0.60, 95% CI: 0.52–0.68),
residents of Taipei (OR= 0.75, 95% CI: 0.58–0.96) as well as farmers and fishermen (OR= 0.71, 95% CI: 0.54–0.94), but was
higher in residents of central Taiwan (OR= 1.99, 95% CI: 1.56–2.54. Most biomedicine and TCM outpatient services were
provided by private clinics, followed by private hospitals. The two most frequently recorded coexisting diseases for
both biomedicine and TCM outpatient visits specifically for liver cancer were (1) chronic liver disease and cirrhosis, and
(2) malignant neoplasm of the liver and hepatic bile duct. The mean fee per visit for biomedicine was much higher
than that for TCM, and the average expenditure was NT$429.73 (US$13.25) per biomedicine visit and NT$301.93
(US$9.32) per TCM visit (US$1 =NT$32.4 in 2007). For outpatient visits specifically for liver cancer, the mean fee per visit
for biomedicine was much higher than that for TCM. The average cost per visit was NT$1457.31 (US$44.98) for
biomedicine and NT$1080.76 (US$33.36) for TCM.
Conclusion: TCM was widely used by the patients with liver cancer, and the prevalence of TCM use remained stably
high during the study period. The costs of insurance covering TCM were consistently lower than those covering
biomedicine in patients with liver cancer. The findings of this study should be useful for health policy makers as well as
researchers considering the integration of TCM and biomedicine.* Correspondence: tcli@mail.cmu.edu.tw; jglin@mail.cmu.edu.tw
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Incidence and mortality of liver cancer (LC)
LC is the leading cause of cancer-related mortality world-
wide. Mongolia, Gambia, Taiwan, China, and Thailand
have the highest incidence rates of LC in the world,
and their age standardized incidence rates in 2008 were
94.4, 36.1, 35.7, 33.8, and 29.3 per 100 000 persons, re-
spectively [1]. In Taiwan, LC accounts for more than
28% of total deaths [2], and ranks as the second most
common cancer in both men and women, accounting
for about 20% of all cancer deaths. The annual standar-
dized mortality incidence increased from 22.7/100 000
in 1991 to 26.2/100 000 in 2009 [2]. In China, LC
accounts for more than 10% of total deaths and ranks
as the fourth most common cancer [3].
Use of Complementary and Alternative Medicine
worldwide
The use of Complementary and Alternative Medicine
(CAM) has gained worldwide popularity. The motives
for the use of CAM include perceived failure of standard
health care, the need of a patient for autonomy, and pre-
ference for holistic or natural therapy in Western popu-
lations [4-6]. CAM is commonly used together with
conventional medicine and has entered mainstream soci-
ety and culture [7-9]. According to the 2007 National
Health Interview Survey, the prevalence of CAM use is
about 38% in American adults [9]. In a survey across a
number of European countries, the percentages of CAM
use range from 22.7% for head and neck cancer patients
to 56.3% for pancreatic cancer patients [10].
Use of Traditional Chinese Medicine (TCM) in Asian
countries
TCM is one of the most popular CAM forms worldwide.
The motives for TCM use include cultural belief about
TCM in managing illness symptoms, maximizing con-
ventional treatment effect, and preventing recurrence in
Chinese populations [11-13]. TCM is commonly used
together with conventional medicine and has entered
mainstream society and culture. In Chinese and East
Asian societies, TCM plays an active role in the modern
health care system. Unlike CAM that is not funded by
either private or social insurance companies in most
Western societies, TCM is covered by the National
Health Insurance (NHI) Program of Taiwan. Thus, one
important feature of the NHI Program is the coverage of
both biomedicine (Western) and TCM. By 2003, after
implementing the NHI Program, more than 99% of the
23 million persons residing in Taiwan had been covered
by this universal health insurance plan. Compared with
CAM use by Western populations, TCM has a higher
level of accessibility due to lesser financial barrier. A
study on the determinants of TCM and acupunctureutilization of cancer patients in Taiwan has shown that
the prevalence of TCM ranges from 14.81% for cervical
cancer to 30.13% for breast cancer [8].Therapeutic effect of TCM against hepatocellular
carcinoma (HCC) in previous studies
Treatment with TCM has been investigated for its effect
on the stimulation of host immune response that has
cytotoxic activity against HCC. TCM is commonly used
in combination with transcatheter arterial chemoemboli-
zation (TACE) to treat patients with unresectable HCC
[14-16]. The findings of a meta-analysis of 37 rando-
mized controlled trials involving 2653 patients reveal
that TCM plus TACE improves patient survival, quality
of life, alleviation of symptoms, and tumor response
[14]. In another meta-analysis, TCM plus TACE signifi-
cantly increases the survival, complete or partial response,
non-deterioration performance, T cells, natural killer cells,
and white blood cell count; significantly decreases the
level of blood alpha-fetoprotein concentration; and signifi-
cantly lowers the risk for nausea and vomiting [15]. A re-
cent meta-analysis has also demonstrated that TCM plus
TACE increases the proportions of cluster differentiation
(CD) 3(+) T cells, CD4(+) T cells, and natural killer cells,
as well as the ratio of CD4(+)/CD8(+) before and after
treatment [16]. A meta-analysis of randomized controlled
trials for TCM combined with chemotherapy has reported
promising evidence that TCM plus chemotherapy may
benefit patients with HCC [17]. The most commonly used
ingredients demonstrated to have oncologic and immuno-
logic pharmacology are Astragalus, Panax ginseng, toad
skin secretions (bufotoxin), beetle extracts (Mylabris),
Atractylodes, Bupleurum, and Curcuma [18].How the current study helps resolve the uncertainties
regarding TCM use
Previous studies have explored the utilization of TCM
either in a general population [19-24], in a single clinical
setting [25], or for acupuncture use only [26]. Two stud-
ies have described the use frequencies, characteristics of
users, and disease categories treated by TCM in Taiwan
from 1996 to 2001 [27] and from 1997 to 2003 [28]
using complete NHI datasets for TCM. A recent study
has explored TCM use among all prostate cancer
patients in the NHI datasets in 2007 [29]. However,
TCM use among patients with LC has not yet been
reported. This study aimed to compare the differences
between the characteristics, types of care provider,
existing diseases, and expenditures for outpatient ser-
vices of TCM and non-TCM users with LC enrolled in
the NHI Program in Taiwan from 1996 to 2007 using a
population-based random sample of one million insured
patients.
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Data sources
The NHI program was initiated in Taiwan in 1995 and
currently covers about 99% of the 23 million population of
Taiwan. The national government-run Bureau of National
Health Insurance (BNHI) has contracted with 97% of all
hospitals and 92% of all clinics nationwide. The BNHI
conducts an expert review of random samples of every
50–100 ambulatory and inpatient claims in each hospital
and clinic quarterly, and false reports of diagnosis are
severely penalized [30]. The NHI Research Database
(NHIRD) provides registration and claim datasets from a
random sample of one million beneficiaries for use in
research. The data for the present study was obtained
from the Longitudinal Health Insurance Database 2005
(LHID2005), which was released by the Taiwan National
Health Research Institute in 2007. The LHID2005 con-
tains all ambulatory and inpatient claim data of one mil-
lion beneficiaries who were randomly sampled from 23
million enrollees in the NHI. The distributions of the
beneficiary age and gender in the LHID2005 and original
NHI database are similar.
A retrospective study was conducted using the regis-
tration and claim datasets for the years 1996–2007 from
the LHID2005. The LHID2005 database contains com-
prehensive information, such as demographic data, dates
of clinical visits, diagnostic codes, expenditure amounts,
and others. The amount of expenditure in the dataset
was that covered by the NHI Program, which repre-
sented the consumption of medical resources. The NHI
Program has a committee that reviews new treatments,
drugs, and procedures, and only those that prove to have
evidence-based effectiveness are covered. The expend-
iture can be classified into the following categories: fees
for consultation, treatment, and medical supply; diagno-
sis fee; and drug fee. Files of registry for beneficiaries,
ambulatory care expenditures by visits, and inpatient
care by admission were obtained for analysis. To protect
privacy, data on the patient identities and institutionsFigure 1 Proportion of traditional Chinese medicine use by liver cancwere scrambled cryptographically by the NHIRD. Patients’
privacy is under protection form using these data. Our
study using these data are exempted from institutional
review board approval of Public Health, Social and
Behavioral Science Committee Research Ethics Com-
mittee, China Medical University and Hospital.
The NHI covered TCM outpatient care, but not in-
patient care. Therefore, only TCM and biomedicine am-
bulatory care were analyzed in this study. The outpatient
datasets contained encounter form-based date of visits,
patient gender and date of birth, medical facility visited,
department visited, prescribing physician, dispensing
pharmacist, three items from the International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes, primary procedure (e.g., drug or
diagnostic procedure), type of copayment, billed amount,
and paid amount.Statistical analysis
Continuous variables were reported as mean and 95%
confidence interval (CI), and categorical variables were
reported as number, percentage, and 95% CI. Differences
in proportions and means were assessed using a χ2-test
or a t-test. Adjusted odds ratios (ORs) were estimated by
multivariate logistic regression analysis. Simple linear re-
gression was used to examine the annual trend of TCM
use in 1996–2007. All reported p values were those of
two-sided tests. The statistical significance was set at
p < 0.05. All analyses were performed using SAS version
9.1 (SAS Institute Inc., Cary, NC, USA).Results
Prevalence of TCM use over time
A total of 6,358 LC patients used ambulatory care in
1996–2007. Among them, 1,240 (19.50%) used TCM
outpatient services. Figure 1 shows the prevalence of
TCM use during the study period. The prevalence of
TCM use fluctuated and had a peak of 25.11% in 2001.er patients during the years 1996–2007.
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β=−0.0369, p = 0.8689).
Factors associated with TCM use
The demographics are presented in Table 1 according to
the status of TCM use. The mean patient age was
57.95 years (SD= 11.46) for TCM users and 59.65 years
(SD= 12.30) for non-users. After multivariable adjust-




Age 59.65 ± 12.30
<50 (reference) 1315 2
50s 1283 2
60s 1274 2
>= 70s 1246 2
Gender
Female (reference) 1957 3
Male 3161 6
Insured amount (NT$/month)
<20,000 (reference) 3491 6
20,000-39,999 964 1
40,000-59,999 459 8
>= 60,000 204 3
Urban Level




>= 5 546 1
Residential Area







Government, school employees (reference) 530 1
Private enterprise employees 1390 2
Member of occupational 960 1
Farmers, fishermen 1215 2
Low-income households Veterans, other regional 752 1
TCM: traditional Chinese Medicine; OR: odds ratio; CI: confidence interval.
a: Adjusted ORs were from the model considering age, gender, insured amount, resparticipants aged 70 years and older (odds ratio, OR=
0.79, 95% confidence interval, CI: 0.64–0.97, males
(OR= 0.60, 95% CI: 0.52–0.68), residents of Taipei (OR=
0.75, 95% CI: 0.58–0.96) as well as farmers and fishermen
(OR=0.71, 95% CI: 0.54–0.94), but was higher in residents
of central Taiwan (OR=1.99, 95% CI: 1.56–2.54). There
was no significant difference between the insured amount
and urbanization level of TCM users and nonusers. We fur-
ther categorized TCM users into TCM only users and1996–2007






5.69 343 27.66 1.00
5.07 383 30.89 1.15 0.97-1.37
4.89 275 22.18 0.84 0.69-1.02
4.35 239 19.27 0.79 0.64-0.97
8.24 631 50.89 1.00
1.76 609 49.11 0.60 0.52-0.68
8.21 815 65.73 1.00
8.84 245 19.76 0.92 0.77-1.11
.97 121 9.76 1.01 0.78-1.30
.99 59 4.76 1.21 0.87-1.70
9.19 348 28.74 1.00
9.29 358 29.56 0.91 0.75-1.10
4.19 187 15.44 0.91 0.71-1.15
6.38 201 16.6 0.85 0.66-1.08
0.95 117 9.67 0.80 0.58-1.08
3.03 149 12.02 1.00
7.57 383 30.89 0.75 0.58-0.96
3.85 306 24.68 1.99 1.56-2.54
8.19 215 17.34 1.12 0.86-1.44
.74 28 2.26 1.40 0.83-2.36
5.3 153 12.34 0.91 0.69-1.18
0.93 158 13.4 1.00
8.68 361 30.62 0.92 0.73-1.15
9.81 271 22.99 0.99 0.77-1.27
5.07 246 20.87 0.71 0.54-0.94
5.51 143 12.13 0.80 0.60-1.07
idential area, and insured unit.
Table 2 Liver cancer outpatient service providers during the period 1996-2007
Outpatient visits specifically for
liver cancer Characteristic
Biomedicine TCM users P value for
Visits Percentage (95%CI) Visits Percentage (95%CI) χ2
Type of providers <0.001
Public hospitals 75716 11.91 (11.83-11.99) 20455 8.98 (8.86-9.1)
Public Chinese medicine hospitals 34 0.01 (0.01-0.01) 636 0.28 (0.26-0.30)
Private hospitals 250469 39.40 (39.28-39.52) 70631 30.99 (30.80-31.18)
Private Chinese medicine hospitals 326 0.05 (0.04-0.06) 2754 1.21 (1.17-1.25)
Public clinics 20175 3.17 (3.13-3.21) 4253 1.87 (1.81-1.93)
Private clinics 252442 39.71 (39.59-39.83) 120067 52.69 (52.49-52.89)
Unknown 36543 5.75 (5.69-5.81) 9098 3.99 (3.91-4.07)
Total 635705 100 227894 100
TCM: traditional Chinese medicine; CI: confidence interval.
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those of biomedicine only users are shown in Additional file
1.
Medical institutes
Most biomedicine outpatient services were provided by
private clinics (39.71%), followed by private hospitals
(39.4%) (Table 2). Similarly, the majority of TCM out-
patient services were provided by private clinics (52.69%)
and private hospitals (30.99%). The remaining TCM out-
patient services were provided by public hospitals (8.98%).
The proportion of TCM outpatient services provided by
private clinics was much higher than that of biomedicine
outpatient services provided by private clinics (52.69% vs.
39.71%, p < 0.001).
Existing diseases
The diagnoses in all ambulatory claim data were
recorded in the ICD-9-CM format. The five most fre-
quently recorded existing disease codes for biomedicine
and TCM outpatient visits specifically for LC as well as
for all outpatient visits are presented in Table 3. For out-
patient visits specifically for LC, the four (out of five)
most frequently recorded existing diseases for both bio-
medicine and TCM were (1) chronic liver disease and
cirrhosis, (2) malignant neoplasm of the liver and hepatic
bile ducts, (3) essential hypertension, and (4) acute upper
respiratory infections. In contrast, diabetes mellitus was
the third most frequently recorded existing disease for bio-
medicine, whereas general symptoms were the third most
frequently recorded existing disease for TCM. For all out-
patient visits, the four (out of five) most frequently
recorded existing diseases for both biomedicine and TCM
were (1) acute upper respiratory infection, (2) essential
hypertension, (3) diabetes mellitus, and (4) general symp-
toms. In contrast, conjunctival disorders was the fifth
most frequently recorded existing disease for biomedicine,whereas other and unspecified disorders of the back were
the fourth most frequently recorded existing disease for
TCM.
Expenditures
Table 4 shows the details of expenditures. Biomedicine
outpatient services accounted for 72.73% of all outpatient
visits and 77.61% of total expenditures, whereas TCM out-
patient services accounted for 27.28% of visits and 22.39%
of expenditures. The fees for consultation, treatment, and
medical supplies, as well as drugs per visit for biomedicine
were markedly higher than those for TCM. The average
expenditure was NT$429.73 (US$13.25) per biomedicine
visit and NT$301.93 (US$9.32) per TCM visit, and the
average cost per visit was NT$981.01 (US$30.28) for bio-
medicine and NT$754.38 (US$23.28) for TCM (p< 0.001
for all comparisons) (US$1=NT$32.4 in 2007). The ratio
of medical expenses for all biomedicine outpatient visits
relative to that for TCM was 3.47, whereas the ratio of the
average medical expenses for each biomedicine outpatient
visit relative to that for TCM was 1.3.
For outpatient visits specifically for LC, biomedicine
outpatient services accounted for 73.61% of all visits and
79.00% of total expenditures, whereas TCM outpatient
services accounted for 26.39% of visits and 21.00% of
expenditures. The fees for consultation, treatment, and
medical supplies, as well as drugs per visit for biomedi-
cine were markedly higher than those for TCM. The
average expenditure was NT$739.58 (US$22.83) per bio-
medicine visit and NT$506.59 (US$15.64) per TCM visit.
The average cost per visit was NT$1457.31 (US$44.98)
for biomedicine and NT$1080.76 (US$33.36) for TCM
(p < 0.001 for all comparisons). The ratio of medical
expenses for all biomedicine outpatient visits relative to
that for TCM was 3.76, whereas the ratio of the average
medical expenses for each biomedicine outpatient visit
relative to that for TCM was 1.35.
Table 3 Top 5 disease codes among liver cancer patients during the years 1996–2007 for all outpatient visits and
outpatient visits specifically for liver cancer
Western medicine Traditional chinese medicine
Ranking Disease (Code) No. Percentage (95% CI) Disease (Code) No. Percentage (95% CI)
Outpatient visits specifically for liver cancer
Total = 1,181,130 Total = 384,074
1 Chronic liver disease and
cirrhosis (571)
84,263 7.31 (7.26-7.36) Chronic liver disease and cirrhosis (571) 22,419 5.84 (5.77-5.91)
2 Malignant neoplasm of the liver
and hepatic bile ducts (155)
75,881 6.42 (6.38-6.46) Malignant neoplasm of the liver
and hepatic bile ducts (155)
1,9847 5.17 (5.10-5.24)
3 Diabetes Mellitus (250) 49,506 4.19 (4.15-4.23) General symptoms (780) 13,060 3.4 (3.34-3.46)
4 Essential hypertension (401) 48,762 4.13 (4.09-4.17) Acute upper respiratory infections (465) 12,231 3.18 (3.12-3.24)
5 Acute upper respiratory
infections (465)
40,502 3.43 (3.40-3.46) Essential hypertension (401) 11,604 3.02 (2.97-3.07)
Ranking Disease (Code) No. Percentage (95%CI) Disease (Code) No. Percentage (95%CI)
All outpatient visits
Total = 86,850,726 Total = 29,277,941
1 Acute upper respiratory
infections (465)
5,932,918 6.84 (6.83-6.85) Acute upper respiratory infections (465) 1,757,625 6.00 (5.99-6.01)
2 Essential hypertension (401) 3,884,150 4.47 (4.47-4.47) General symptoms (780) 857,752 2.93 (2.92-2.94)
3 Diabetes Mellitus (250) 3,027,309 3.49 (3.49-3.49) Essential hypertension (401) 805,130 2.75 (2.74-2.76)
4 General symptoms (780) 2,030,401 2.34 (2.34-2.34) Other and unspecified disorders
of the back (724)
706,248 2.41 (2.40-2.42)
5 Disorders of conjunctica (372) 1,642,787 1.89 (1.89-1.89) Diabetes Mellitus (250) 635,054 2.17 (2.16-2.18)
CI: confidence interval.
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This study is the first large-scale survey focusing on
TCM use among LC patients in Taiwan. The overall
prevalence of insurance-covered TCM use in outpatient
services among LC patients was 19.50% and remained
stably high during the study period. TCM outpatient ser-
vices accounted for 27.28% of the visits and 22.39% of
the outpatient service expenditures of patients with LC.
The costs of insurance covering TCM were consistently
lower than those covering biomedicine.
The findings on the prevalence of TCM use in patients
with LC were similar to those of previously studied
patients with mild diseases or prostate cancer [28,29].
The prevalence of TCM utilization in our study was
higher than that reported by Lin et al. [29] for patients
with prostate cancer (19.50% vs. 2.6%). One possible ex-
planation is that TCM is more frequently used by
patients with LC because the disease severity of LC
requires more intensive treatment and patients with LC
are inclined to seek alternative treatments. Another pos-
sible explanation is that only outpatient visits specific for
prostate cancer have been considered in the study of Lin
et al. [29], whereas all outpatient visits were considered
in the current work.
Our results suggested that TCM services were utilized
more often by females and residents of central Taiwan,
but less often by patients >70 years old, residents ofTaipei, as well as farmers and fishermen. The higher
TCM use of central Taiwan residents may probably be
due to the higher availability of TCM providers in this
area. Before 1998, the only medical university that pro-
vided formal TCM education was located in central Tai-
wan; thus, the ratio of TCM physicians to 10 000
residents was 1090 for Taichung city in central Taiwan
compared with 771 for the second highest area in 2010.
There are two possible reasons that can explain the low
TCM use of farmers and fishermen. One is that farmers
and fishermen live in areas with less access to TCM pro-
viders. Another is that their economic status is usually
lower and the extra expenditure for TCM use may be a
financial burden. Further research on the barriers for
TCM use is warranted.
Based on the ICD-9-CM codes, we found that chronic
liver disease and cirrhosis, as well as general symptoms
were the primary indications for TCM. In biomedicine,
the top two primary indications, apart from malignant
neoplasm of the liver and hepatic bile ducts, were
chronic liver disease and cirrhosis, as well as diabetes.
These findings on the disease pattern of health care use
may be explained by the fact that patients seek TCM to
relieve symptoms. A recent systematic review of qualita-
tive and quantitative studies regarding the views on trad-
itional Chinese medicine amongst Chinese populations
worldwide found that patients worldwide had a common
Table 4 Expenditures for outpatient services for liver cancer patients (NT$) during the period 1996-2007
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TCM: traditional Chinese medicine; *:p < 0.001; CI: confidence interval.
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fective complement to western medicine (WM) for treat-
ing chronic or serious diseases [31]. Their finding may
explain why LC patients in Taiwan like to seek TCM
treatments for relieving their “general symptoms”.
We observed that the proportions of hypertension and
diabetes only accounted for a small portion of all ICD-9
codes made by patients with LC. Caution should be taken
when interpreting these proportions. This proportion was
affected by both the disease prevalence among Taiwanese
LC patients and the rate of outpatient utilization for each
disease by LC patients with co-existing conditions. This
proportion is also related to insufficient comprehensive
coding. For example, only three diseases were coded if a
patient sought outpatient care for more than three dis-
eases. Our data underestimated the proportion of existing
disease among all ICD-9 codes.
Using data of liver cancer patients from a representa-
tive sample of Taiwan population, we found that women
had higher TCM use than men. This finding is consist-
ent with those that had been conducted in general
population in Taiwan [32], patients with chronic non-
communicable disease [33] and patients with schizo-
phrenia in Hong Kong [34]. Women have been found tobe more predisposed to report their health as poor,
which has been hypothesized that this result from
women’s health beliefs and help-seeking behavior [35].
There are two possible reasons why patients who aged
70 years and older or who were farmers and fishermen
had lower TCM use than their counterparts. First, they
lived in rural areas with lower density of medical services,
especially TCM. Previous studies exploring the factors
associated with TCM uses in Taiwan have found that
people living in rural areas are less likely to access various
conventional or unconventional therapies [28,36,37]. Sec-
ond, the socioeconomic status (SES) of these individuals is
usually low and low SES has been reported to be asso-
ciated with low TCM use [38].
In Taiwan, the national health insurance program
includes both biomedicine and TCM. Under two modal-
ities of medicine within one health care system, it
enhances the high availability and affordability of these
two types of health care services, thus improves the
quality, comprehensiveness, and efficiency of care. How-
ever, the majority of the TCM services were provided by
the private sector. Public hospitals or clinics did not set
up TCM departments until recent years because of
popularity of TCM worldwide. Up to date, not all public
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patients who seek for health care service in public hospi-
tals or clinics are veterans or individuals living in rural
area or with low SES. It would increase the difficulty to
bring biomedicine and TCM care together for those
patients seeking care in public hospitals or clinics.
Developing strategies to overcome the barrier for these
individuals would be an important task for health care
planners and policy makers.
The strength of this study is that it is the first large-
scale study of TCM use in Taiwanese society, and the
NHI databases are representative of the general popula-
tion in Taiwan because the NHI Program covers more
than 99% of Taiwan’s 23 million population and 93% of
the medical institutes. Previous studies on health care
utilization with regard to TCM/CAM use have been
conducted with clinic attendees, telephone interviews,
self-administered interviews, household interviews, as
well as hospital and private clinic surveys. These studies
usually have limited sample sizes, and have been con-
ducted in countries in which TCM/CAM is not covered
by insurance. Thus, the pattern and characteristics of
TCM/CAM use may be affected by the socioeconomic
status of individuals.
There are several limitations to this study. First, our
study is a kind of administrative database research and
uses ICD-9-CM codes to identify patients with LC and
use drug and diagnosis procedure for care costs [39].
Misclassification errors from this type of research are in-
evitable. Second, some herbal medicines not covered by
NHI and visits at clinics not under contract with the
BNHI were not considered. About 10% of TCM clinics
are not under contract with the BNHI because the NHI
payment is low. Some patients may also be taking de-
coction forms of Chinese medicine, which is not cov-
ered by the NHI Program. Hence, the NHIRD data may
lead to an underestimation of TCM costs. Third, clin-
ical and biochemical measurements, such as staging
and alpha fetal protein, were not included in the study;
thus, the TCM use and costs stratified by these factors
cannot be explored.Conclusion
The NHI Program of Taiwan is a comprehensive and uni-
versal health insurance program that covers both conven-
tional biomedicine and TCM services. The prevalence of
TCM use among LC patients remained stably high. The
costs of insurance-covered TCM were consistently lower
than those of biomedicine. This study provided informa-
tion on TCM use frequency as well as coexisting diseases
treated by biomedicine and TCM in LC patients, which
should be useful to health policy makers and practitioners
who consider the integration of TCM and biomedicine.Additional file
Additional file 1: Table 1. Liver cancer patient Biomedicine and TCM
services during the period 1996–2007.
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